Interventional × Vorinostat × Dermatologic × Clear all
NCT00601718 2017-05-25

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

University of Washington

Phase 1/2 Completed
29 enrolled 10 charts
NCT00499811 2014-02-24

Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
15 enrolled
NCT00005634 2013-06-19

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
NCT00045006 2013-05-30

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT01116154 2010-12-09

Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

City of Hope Medical Center

Phase 1 Terminated
30 enrolled